Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study

Fig. 1

Patient inclusion flowchart. Participants who were prescribed with the first-line bDMARDs during 2011 and 2019 were included after excluding other rheumatoid arthritis or juvenile rheumatoid arthritis, development of herpes zoster within 1 month after bDMARDs, and recurrent herpes zoster that occurred within 6 months since the date of the previous herpes zoster infection

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us